FR2485015A1 - Derives de l'olivacine et leur application therapeutique - Google Patents
Derives de l'olivacine et leur application therapeutique Download PDFInfo
- Publication number
- FR2485015A1 FR2485015A1 FR8013565A FR8013565A FR2485015A1 FR 2485015 A1 FR2485015 A1 FR 2485015A1 FR 8013565 A FR8013565 A FR 8013565A FR 8013565 A FR8013565 A FR 8013565A FR 2485015 A1 FR2485015 A1 FR 2485015A1
- Authority
- FR
- France
- Prior art keywords
- hydroxy
- olivacinium
- nothing
- olivacine
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WBGUTGOSUBJTJZ-UHFFFAOYSA-N 1,5-dimethyl-2H-pyrido[4,3-b]carbazole Chemical class Cc1[nH]ccc2c(C)c3nc4ccccc4c3cc12 WBGUTGOSUBJTJZ-UHFFFAOYSA-N 0.000 title abstract description 23
- 230000001225 therapeutic effect Effects 0.000 title description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 40
- 239000002253 acid Substances 0.000 claims abstract description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 5
- 239000012458 free base Substances 0.000 claims abstract description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 3
- 239000011707 mineral Substances 0.000 claims abstract description 3
- ZIXGXMMUKPLXBB-UHFFFAOYSA-N Olivacine Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C1C=CN=C(C)C1=C2 ZIXGXMMUKPLXBB-UHFFFAOYSA-N 0.000 claims description 33
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 239000002585 base Substances 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000003282 alkyl amino group Chemical group 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 150000007522 mineralic acids Chemical class 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 150000001242 acetic acid derivatives Chemical class 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 150000001450 anions Chemical class 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 claims description 2
- 229940102223 injectable solution Drugs 0.000 claims description 2
- 150000003893 lactate salts Chemical class 0.000 claims description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 10
- -1 HYDROXY GROUP Chemical group 0.000 abstract description 6
- 238000011282 treatment Methods 0.000 abstract description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 2
- 150000007513 acids Chemical class 0.000 abstract description 2
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical group [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen(.) Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 239000013078 crystal Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 10
- 230000001988 toxicity Effects 0.000 description 10
- 231100000419 toxicity Toxicity 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 208000032839 leukemia Diseases 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 229920001429 chelating resin Polymers 0.000 description 6
- 230000033444 hydroxylation Effects 0.000 description 6
- 238000005805 hydroxylation reaction Methods 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- KPJPHPFMCOKUMW-UHFFFAOYSA-N iodomethane Chemical compound I[CH2] KPJPHPFMCOKUMW-UHFFFAOYSA-N 0.000 description 3
- 238000006198 methoxylation reaction Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 241001529936 Murinae Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- 238000005956 quaternization reaction Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- 208000007093 Leukemia L1210 Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241001676573 Minium Species 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- ZRWPUFFVAOMMNM-UHFFFAOYSA-N Patulin Chemical class OC1OCC=C2OC(=O)C=C12 ZRWPUFFVAOMMNM-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241001622803 Thymelicus lineola Species 0.000 description 1
- 125000005011 alkyl ether group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001055 blue pigment Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930005303 indole alkaloid Natural products 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000010450 olivine Substances 0.000 description 1
- 229910052609 olivine Inorganic materials 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8013565A FR2485015A1 (fr) | 1980-06-18 | 1980-06-18 | Derives de l'olivacine et leur application therapeutique |
| EP81400972A EP0042348A1 (fr) | 1980-06-18 | 1981-06-17 | Dérivés de l'olivacine et leur application thérapeutique |
| JP9452381A JPS5728088A (en) | 1980-06-18 | 1981-06-18 | Olibacine derivative and cancer therapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8013565A FR2485015A1 (fr) | 1980-06-18 | 1980-06-18 | Derives de l'olivacine et leur application therapeutique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2485015A1 true FR2485015A1 (fr) | 1981-12-24 |
| FR2485015B1 FR2485015B1 (OSRAM) | 1983-07-08 |
Family
ID=9243238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8013565A Granted FR2485015A1 (fr) | 1980-06-18 | 1980-06-18 | Derives de l'olivacine et leur application therapeutique |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP0042348A1 (OSRAM) |
| JP (1) | JPS5728088A (OSRAM) |
| FR (1) | FR2485015A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2582649A1 (fr) * | 1985-05-29 | 1986-12-05 | Centre Nat Rech Scient | Derives methyles de bis 7h pyridocarbazoles methyles et compositions pharmaceutiques les contenant |
| FR2584409B1 (fr) * | 1985-07-04 | 1987-11-20 | Sanofi Sa | Chlorhydrates de chlorures de derives d'aminoalkyl-2 hydroxy-9 ellipticinium et compositions pharmaceutiques en contenant |
| US4851417A (en) * | 1988-05-26 | 1989-07-25 | Rensselaer Polytechnic Institute | 9-substituted 6H-pyrido[4,3-b]carbazoles |
| US6358931B1 (en) | 1990-01-11 | 2002-03-19 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating RNA |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH396023A (de) * | 1959-11-20 | 1965-07-31 | Wander Ag Dr A | Verfahren zur Herstellung von Pyridocarbazolderivaten |
| FR2308365A2 (fr) * | 1975-04-25 | 1976-11-19 | Anvar | Derives de l'hydroxy-9 ellipticine et leur application therapeutique |
-
1980
- 1980-06-18 FR FR8013565A patent/FR2485015A1/fr active Granted
-
1981
- 1981-06-17 EP EP81400972A patent/EP0042348A1/fr not_active Withdrawn
- 1981-06-18 JP JP9452381A patent/JPS5728088A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH396023A (de) * | 1959-11-20 | 1965-07-31 | Wander Ag Dr A | Verfahren zur Herstellung von Pyridocarbazolderivaten |
| FR2308365A2 (fr) * | 1975-04-25 | 1976-11-19 | Anvar | Derives de l'hydroxy-9 ellipticine et leur application therapeutique |
Non-Patent Citations (3)
| Title |
|---|
| CA1967 * |
| CA1975 * |
| EXBK/79 * |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2485015B1 (OSRAM) | 1983-07-08 |
| JPS5728088A (en) | 1982-02-15 |
| EP0042348A1 (fr) | 1981-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BE851310A (fr) | Nouveaux derives de la tetrahydro-equinocandine b | |
| WO1989002895A1 (fr) | Esters de l'acide n-butyrique et leur utilisation comme medicaments | |
| FR2477016A1 (fr) | Compositions pharmaceutiques a base de derives de mitomycine pour le traitement de maladie neoplastique chez les animaux | |
| US4701570A (en) | Antitumor agent | |
| FR2485015A1 (fr) | Derives de l'olivacine et leur application therapeutique | |
| KR970005346B1 (ko) | 사카라이드 유도체 | |
| EP0117959B1 (fr) | Nouveaux dérivés de la nitrosourée, leur procédé de préparation et les compositions pharmaceutiques les renfermant | |
| LU86059A1 (fr) | Nouveaux analogues 6-substitues de la mitomycine | |
| FR2662940A1 (fr) | Utilisation de derives de la tetrahydro isoquinoleine pour la preparation de medicaments anti-tumoraux, application a titre de medicaments de derives de la tetrahydro isoquinoleine et produits derives de cette structure. | |
| FR2499577A1 (fr) | Nouvelles 1-(2-chloroethyl)-1-nitrosourees-3-substituees par un reste de sucre, utiles notamment comme agents antitumoraux et leur procede de preparation | |
| WO1995018817A1 (fr) | Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant | |
| FR2553663A1 (fr) | Derives du 1,2-dithiolanne, leur preparation et leur utilisation comme medicaments | |
| US4560703A (en) | Clavulone derivatives, process for preparing the same, and use of said compounds | |
| BE1003519A3 (fr) | Nouveaux derives de la carbonyl-2 n,n'-di-(trimethoxybenzoyle) piperazine, un procede pour leur preparation et compositions therapeutiques en contenant. | |
| EP0772630B1 (fr) | Derives de streptogramine, leur preparation et les compositions pharmaceutiques qui les contiennent | |
| CH616937A5 (en) | Process for producing 9-hydroxyellepticine derivatives | |
| EP0482993A1 (fr) | Dérivés N,O spirocycliques de cyclotriphosphazènes, leur préparation et leur application en thérapeutique | |
| FR2510577A1 (fr) | Composes organiques azotes extraits de plantes et leurs derives, leur preparation et leurs utilisations therapeutiques, notamment en tant qu'agents antineoplastiques | |
| EP0179076B1 (fr) | Derives sulfures de l'hydantoine et compositions pharmaceutiques les contenant | |
| KR20040022224A (ko) | 특이 구조를 가진 일 군의 새로운 항암 화합물 | |
| WO2003000208A1 (fr) | Composition a usage topique comprenant un produit cytotoxique | |
| FR2797446A1 (fr) | Derives de phenanthroline-7-ones et leurs applications en therapeutique | |
| FR2508043A1 (fr) | Derives d'aporphine efficaces par voie orale et leur procede de fabrication | |
| FR2569699A1 (fr) | Nouveaux derives de l'aminomethyle-6 furo-(3,4-c)-pyridine ainsi que leur procede de preparation | |
| FR2706463A1 (fr) | Nouveaux dérivés d'aziridino spirodiazaalkylcyclotriphosphazènes substitués leur procédé de préparation et leur utilisation en tant que médicament. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |